Risky Medication During Pregnancy: Unborn Babies at Risk
“`html
Uneven Global Progress in Safe Prescribing of Antiseizure Medications
Table of Contents
A new study reveals important disparities in the use of valproate, an antiseizure medication known to carry risks during pregnancy, across different regions of the world. While higher-income countries have seen declines in its use due to stricter regulations and access to alternatives, valproate remains widely prescribed in areas where newer therapies are less accessible.
Published: November 28, 2023 (Updated for evergreen relevance)
The Global Landscape of Antiseizure Medication Use
Researchers Dr.Adrienne Chan and Professor Ian Wong of Aston University analyzed sales data from numerous countries to assess the global use of antiseizure medications.Their findings, commissioned by the World Health Association (WHO), highlight a critical need for improved education and access to safer alternatives.
The study focused on valproate, a medication effective in treating various types of seizures and bipolar disorder, but which carries a significant risk of major birth defects and neurodevelopmental problems when taken during pregnancy. The WHO estimates that epilepsy affects over 50 million people worldwide, making access to effective treatment crucial.
Regional Disparities and Access to Treatment
In many higher-income countries, stricter regulations and extensive pregnancy prevention programs have successfully reduced valproate prescriptions. These programs often include detailed counseling for women of childbearing age about the risks associated with valproate and the availability of alternative treatments. For example, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued strong warnings and guidance regarding valproate use in women of childbearing potential.
However, in other regions, particularly those with limited resources, newer antiseizure therapies remain prohibitively expensive or challenging to obtain. This leads to continued reliance on valproate, despite its known risks. The cost of newer medications can be several times higher than valproate, creating a significant barrier to access for many patients.
| Region | Valproate Use Trend | Access to Alternatives |
|---|---|---|
| high-Income Countries (e.g., Europe, North America) | Declining | Good |
| Middle-Income Countries (e.g., Latin America, parts of Asia) | Variable | Moderate |
| Low-Income Countries (e.g., Sub-Saharan Africa) | High | Limited |
The WHO’s Role and Future Research
the